Home » Stocks » PLx Pharma

PLx Pharma Inc. (PLXP)

Stock Price: $3.53 USD 0.32 (9.97%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $3.54 +0.01 (0.28%) Aug 11, 6:13 PM

Stock Price Chart

Key Info

Market Cap 32.32M
Revenue (ttm) 250,427
Net Income (ttm) -8.15M
Shares Out 9.16M
EPS (ttm) -1.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $3.53
Previous Close $3.21
Change ($) 0.32
Change (%) 9.97%
Day's Open 3.46
Day's Range 3.27 - 3.60
Day's Volume 22,198
52-Week Range 1.80 - 6.53

More Stats

Market Cap 32.32M
Enterprise Value 26.41M
Earnings Date (est) Aug 14, 2020
Ex-Dividend Date n/a
Shares Outstanding 9.16M
Float 6.83M
EPS (basic) -1.17
EPS (diluted) -1.10
FCF / Share -1.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 137,740
Short Ratio 25.04
Short % of Float 1.82%
Beta 4.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 129.06
PB Ratio n/a
Revenue 250,427
Operating Income -14.29M
Net Income -8.15M
Free Cash Flow -13.39M
Net Cash 5.91M
Net Cash / Share 0.65
Gross Margin 225.80%
Operating Margin -5,705.31%
Profit Margin -3,752.80%
FCF Margin -5,345.27%
ROA -41.93%
ROE -119.78%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$10.00*
Low
10.0
Current: $3.53
High
10.0
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.570.750.780.02----
Revenue Growth-24.92%-3.28%3793.29%-----
Gross Profit0.570.750.780.02----
Operating Income-14.20-10.96-15.85-4.81-18.76-13.58-4.01-1.84
Net Income-20.500.90-15.35-4.91-18.74-13.58-4.01-1.84
Shares Outstanding8.928.737.024.381.180.980.58-
Earnings Per Share-3.840.10-2.19-1.12-15.92-13.84-6.96-
Operating Cash Flow-12.66-9.50-13.31-1.81-14.59-11.28-2.19-1.54
Capital Expenditures-0.23-0.65-0.54-----
Free Cash Flow-12.89-10.15-13.84-1.81-14.59-11.28-2.19-1.54
Cash & Equivalents14.0014.2524.400.0632.2127.043.861.46
Total Debt4.287.196.941.78----
Net Cash / Debt9.727.0617.46-1.7232.2127.043.861.46
Assets18.5018.3928.850.6232.4127.214.031.47
Liabilities16.9311.9424.232.941.611.260.820.16
Book Value-12.096.444.62-2.3230.8025.953.211.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PLx Pharma Inc.
Country United States
Employees 10
CEO Natasha Giordano

Stock Information

Ticker Symbol PLXP
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PLXP

Description

PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral non-steroidal anti-inflammatory drugs using the PLxGuard delivery system, such as PL1200 Ibuprofen 200 mg, a GI-safer ibuprofen product for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. The company was founded in 2002 and is based in Sparta, New Jersey.